%0 Journal Article
%T The health system impact of false positive newborn screening results for medium-chain acyl-CoA dehydrogenase deficiency: a cohort study
%A Aizeddin Mhanni
%A Anne-Marie Laberge
%A Annette Feigenbaum
%A Astrid Guttmann
%A Beth K. Potter
%A Brenda J. Wilson
%A Cheryl Rockman-Greenberg
%A Chitra Prasad
%A Christine Davies
%A Deshayne B. Fell
%A Doug Coyle
%A Fiona A. Miller
%A John J. Mitchell
%A Jonathan B. Kronick
%A Kumanan Wilson
%A Linda Dodds
%A Maria D. Karaceper
%A Marni Brownell
%A Meranda Nakhla
%A Pranesh Chakraborty
%A Rebecca Sparkes
%A Scott D. Grosse
%A Steven Hawken
%A on behalf of the Canadian Inherited Metabolic Diseases Research Network
%J Archive of "Orphanet Journal of Rare Diseases".
%D 2016
%R 10.1186/s13023-016-0391-5
%X There is no consensus in the literature regarding the impact of false positive newborn screening results on early health care utilization patterns. We evaluated the impact of false positive newborn screening results for medium-chain acyl-CoA dehydrogenase deficiency (MCADD) in a cohort of Ontario infants
%K Neonatal screening
%K Metabolic diseases
%K Health services utilization
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741015/